A Small-Molecule CD4-Mimetic Compound Protects Bone Marrow-Liver-Thymus Humanized Mice From HIV-1 Infection.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29617845.
- Also identified by DOI 10.1093/infdis/jiy174 and PMC identifier 6049021.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Small-molecule CD4-mimetic compounds (CD4mc) inhibit human immunodeficiency virus (HIV-1) entry by blocking binding to the CD4 receptor and by premature triggering of the viral envelope glycoprotein (Env) spike. The efficacy of a CD4mc in protecting bone marrow-liver-thymus (BLT) humanized mice from vaginal HIV-1 challenge was evaluated. Intravaginal application of the CD4mc JP-III-48, either before or simultaneously with virus challenge, protected BLT humanized mice from HIV-1JR-CSF infection in a dose- dependent manner. The direct antiviral effects of a CD4mc prevent HIV-1 infection in a murine model of sexual transmission.
Medical subject headings
- Biomimetics
- CD4 Antigens
- HIV Fusion Inhibitors
- HIV Infections
- HIV-1